Perry Kirk, an insider at Kenvue Inc (KVUE), sold 51,948 shares of the company on December 14, 2025, at a price of $17.21 per share. This transaction amounted to a total value of $894,000. Following this sale, Kirk retains 51,948 shares in Kenvue.
Kenvue, a consumer health company headquartered in Summit, New Jersey, focuses on manufacturing and selling healthcare products, including cosmetics, drugs, and medical devices. The company, which went public on May 4, 2023, has a market capitalization of $33.1 billion and operates under well-known brands such as Tylenol, Neutrogena, and Listerine. With a P/E ratio of 23.10 and an EPS of 0.74, Kenvue is positioned in the essential health, skin health and beauty, and self-care segments.
Insider selling can occur for various reasons, including diversification and personal financial needs. While large sales may attract attention, they do not inherently indicate negative sentiment towards the company. Investors are advised to consider insider transactions as part of a broader analysis, examining patterns over time and across multiple insiders.
Kenvue is scheduled to report its upcoming earnings on February 4, 2026, with an estimated EPS of $0.23 and revenue expectations of $3.8 billion. This update provides insight into the ongoing activities and financial health of the company, which employs 22,000 full-time staff globally.